Meeting
2023 ASCO Annual Meeting
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
Authors
Jian-Qing Mi
State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China
Jian-Qing Mi , Wan-Hong Zhao , Li-Juan Chen , Wei-Jun Fu , Bai-Yan Wang , Jie Xu , Jie Liu , Shi-Wei Jin , Han Zhu , Juan Du , Hua Jiang , Huabin Sun , Yehui Jia , Xiao-Hu Fan , Jian-Yong Li , Jian Hou , Zhu Chen , Wang-Gang Zhang , Ai-Li He , Sai-Juan Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders
Clinical Trial Registration Number
NCT03090659
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8010)
DOI
10.1200/JCO.2023.41.16_suppl.8010
Abstract #
8010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2023 ASCO Annual Meeting
Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.
First Author: Samer Ali Srour
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson
Poster
2021 ASCO Annual Meeting
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
First Author: Luciano J. Costa